BERWYN, Pa., Sept. 16, 2022 /PRNewswire/ — RM LAW, PC announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Abbott Laboratories (“Abbott” or the “Company”) (NYSE:ABT) securities during the period from February 19, 2021 through June 8, 2022inclusive (the “Class Period”).
Abbott shareholders may, no later than October 31, 2022move the Court for appointment as a lead plaintiff of the Class. If you purchased shares of Abbott and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here.
The lawsuit alleges that defendants put profitability ahead of children’s safety. During the Class Period, Abbott Laboratories engaged in a scheme to maximize revenues and inflate its stock price while disregarding and then concealing lapses in safety protocols that ultimately were linked to serious infant illnesses and even deaths.
On February 17, 2022the US Food and Drug Administration (“FDA”) announced that it was investigating four …